No Data
Hong Kong stocks have surged by over 9% today. Stone Medicine-B (02616) has achieved profitability for the first time and successfully entered the international market with its domestic PD-L1 drug, Shugeli monoclonal antibody.
Basestone Pharmaceuticals - B (02616) rose more than 9%, as of the time of publication, it rose 8.59%, to HKD 1.39, with a trading volume of HKD 1.6015 million.
The first half of the year has seen multiple bullish factors combined, and Kasam Pharma (02616) has entered the "best hitting zone".
According to the latest interim report, the fundamentals of Jian Shi Pharmaceutical remain solid, and supported by this, the current valuation of Jian Shi Pharmaceutical has clearly entered the hitting zone, and investment value has emerged.
Express News | CStone Reports 2024 Interim Results and Recent Corporate Updates
CStone Reports 2024 Interim Results and Recent Corporate Updates
Total revenue of RMB 254.2 million for 2024 H1; achieving first-time profitability with cash reserve at RMB 814 million as of June 30, 2024. NDA approval of sugemalimab (PD-L1) for Stage IV NSCLC in
Press Release: CStone Reports 2024 Interim Results and Recent Corporate Updates
Jichuan Pharmaceutical - B (02616) announced its interim performance, with a gross profit of 0.172 billion yuan, a year-on-year increase of 12.12%. The product pipeline has made significant progress.
Kisyo Pharmaceutical-B (02616) announced its interim performance for the six months ending June 30, 2024, during the period...
CStone Pharmaceuticals (HKG:2616) Not Doing Enough For Some Investors As Its Shares Slump 34%
No Data
